World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
30303
World Ranking
12192
National Ranking
6252

Elise C. Kohn publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Elise C. Kohn sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 388 publications — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Elise C. Kohn D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Elise C. Kohn sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 90 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2002 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Elise C. Kohn is affiliated with the National Institutes of Health in the United States. Their principal area of research lies within medicine, with a specific emphasis on oncology, reproductive medicine, epidemiology, neurology, and molecular biology. The scientist has contributed extensively to topics related to ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, neuroendocrine tumor research advances, lung cancer research studies, neuroblastoma research and treatments, endometrial and cervical cancer treatments, and BRCA gene mutations in cancer.

Their recent scholarly contributions include papers published between 2020 and 2022, reflecting ongoing engagement with clinical oncology and cancer therapeutics. Notable recent papers include:

  • Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline (2020) published in Journal of Clinical Oncology
  • PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline (2020) published in Journal of Clinical Oncology
  • Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial (2020) published in The Lancet Oncology
  • Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup (2022) published in The Lancet Oncology
  • Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update (2022) published in Journal of Clinical Oncology

Frequent co-authors collaborating with Elise C. Kohn include:

  • S. Percy Ivy
  • Joyce F. Liu
  • Larry Rubinstein
  • William P. Tew
  • Michael A. Bookman

Publications by Elise C. Kohn appear regularly in several prominent scientific journals, indicating areas of consistent scholarly focus. These publication venues include:

  • Journal of Clinical Oncology
  • Gynecologic Oncology
  • Annals of Oncology
  • JNCI Journal of the National Cancer Institute
  • Cancer

Elise C. Kohn's research primarily addresses challenges in ovarian cancer and related gynecologic malignancies, with an emphasis on molecular therapeutics such as PARP inhibitors.

In recognition of their scientific contributions, Kohn was honored as a Fellow of the American Association for the Advancement of Science (AAAS) in 2002.

Best Publications

  • The microenvironment of the tumour-host interface

    Lance A. Liotta;Elise C. Kohn

  • The MAPK pathway across different malignancies: a new perspective.

    Mauricio Burotto;Victoria L. Chiou;Jung-Min Lee;Elise C. Kohn

  • Serum Proteomic Patterns for Detection of Prostate Cancer

    Emanuel F. Petricoin;David K. Ornstein;Cloud P. Paweletz;Ali Ardekani

  • Molecular Insights into Cancer Invasion: Strategies for Prevention and Intervention

    Elise C. Kohn;Lance A. Liotta

  • Clinical proteomics: translating benchside promise into bedside reality

    Emanuel F. Petricoin;Kathryn C. Zoon;Elise C. Kohn;J. Carl Barrett

  • Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

    Joyce F. Liu;William T. Barry;Michael Birrer;Jung Min Lee

  • Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer

    Monica Brown Jones;Henry Krutzsch;Hungjun Shu;Yingming Zhao

  • Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

    Nilofer S. Azad;Edwin M. Posadas;Virginia E. Kwitkowski;Seth M. Steinberg

  • PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

    Lee Jm;Ledermann Ja;Kohn Ec

  • Angiogenesis: role of calcium-mediated signal transduction.

    Elise C. Kohn;Riccardo Alessandro;Joseph Spoonster;Robert P. Wersto

  • Extracellular matrix promotes mammary epithelial growth and differentiation in vitro.

    Max S. Wicha;George Lowrie;Elise Kohn;P. Bagavandoss

  • High-resolution serum proteomic features for ovarian cancer detection.

    T P Conrads;V A Fusaro;S Ross;D Johann

  • Clinical proteomics: personalized molecular medicine.

    Lance A. Liotta;Elise C. Kohn;Emanuel F. Petricoin

  • Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors.

    Osama M. El-Badry;Caterina Minniti;Elise C. Kohn;Peter J. Houghton

  • What's in the 'BAG'?--A functional domain analysis of the BAG-family proteins.

    Howard Doong;Alysia Vrailas;Elise C. Kohn

  • Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a src-dependent fashion

    Marco Mineo;Marco Mineo;Susan H. Garfield;Simona Taverna;Anna Flugy

  • Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

    Jung Min Lee;Ashley M Cimino-Mathews;Cody J. Peer;Alexandra Zimmer

  • Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.

    Panagiotis A. Konstantinopoulos;Barbara Norquist;Christina Lacchetti;Deborah Armstrong

  • Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.

    Elise C. Kohn;Gisele Sarosy;Annette Bicher;Charles Link

  • Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.

    G Sarosy;E Kohn;D A Stone;M Rothenberg

Frequent Co-Authors

Lance A. Liotta
Lance A. Liotta George Mason University
Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
William D. Figg
William D. Figg National Institutes of Health
Eddie Reed
Eddie Reed National Institutes of Health
Riccardo Alessandro
Riccardo Alessandro University of Palermo
Ursula A. Matulonis
Ursula A. Matulonis Harvard University
Ben Davidson
Ben Davidson Oslo University Hospital
Gordon B. Mills
Gordon B. Mills Oregon Health & Science University
Michael J. Birrer
Michael J. Birrer University of Arkansas for Medical Sciences
Emanuel F. Petricoin
Emanuel F. Petricoin George Mason University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine goes beyond becoming a physician. Many allied health roles and advanced degrees can be accessed through flexible online programs. For nurses aiming for leadership or advanced clinical roles, best online dnp programs provide a path to the highest level of nursing practice, often with affordable options for working professionals.

Students interested in pharmacy can benefit from the cheapest online pharmacy school programs, making pharmacy careers more accessible and cost-effective. For those fascinated by the intersection of healthcare and technology, pursuing a degree in health informatics can open doors to managing medical data, electronic health records, and improving healthcare efficiency.

If you're interested in the business side of medicine, there are also affordable medical billing and coding online courses cost options, which provide in-demand skills for administrative healthcare roles. These career pathways offer diverse opportunities for those passionate about healthcare, even outside of traditional medical school.

Best Scientists Citing Elise C. Kohn

Trending Scientists

Recently Published Articles